|Title:||Pyrrole substituted 2-indolinone protein kinase inhibitors|
|Abstract:|| The present invention relates to pyrrole substituted-2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.|
|Inventor(s):|| Tang; Peng Cho (Moraga, CA), Miller; Todd Anthony (San Marcos, CA), Li; Xiaoyuan (Los Altos, CA), Sun; Connie Li (Palo Alto, CA), Wei; Chung Chen (Foster City, CA), Shirazian; Shahrzad (Corte Madera, CA), Liang; Congxin (Jupiter, FL), Vojkovsky; Tomas (San Mateo, CA), Nematalla; Asaad S. (Concord, CA), Hawley; Michael (Kalamazoo, CA) |
|Assignee:|| Sugen, Inc. (South San Francisco, CA) Pharmacia & Upjohn Co. (Kalamazoo, MI) |
|Filing Date:||Sep 06, 2006|
|Claims:||1. A compound of Formula (I): ##STR00212## wherein: R.sup.1 is hydrogen; R.sup.2 is halo; R.sup.3 is hydrogen; R.sup.4 is hydrogen; R.sup.5 is alkyl; R.sup.6 is --C(O)R.sup.10; R.sup.7 is alkyl; R.sup.10 is --N(R.sup.11)(CH.sub.2).sub.nR.sup.12; R.sup.11 is selected from the group consisting of hydrogen and alkyl; R.sup.12 is --NR.sup.13R.sup.14; R.sup.13 and R.sup.14 combine to form a group selected from the group consisting of --(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, --(CH.sub.2).sub.2O(CH.sub.2).sub.2--, and --(CH.sub.2).sub.2N(CH.sub.3)(CH.sub.2).sub.2--; and n is 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof. |
2. A compound of formula ##STR00213## or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising the compound or salt of claim 2 and a pharmaceutically accepatable carrier or excipient.